76 related articles for article (PubMed ID: 35255603)
1. Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors.
Inaba H; Kaido Y; Ito S; Hirobata T; Inoue G; Sugita T; Yamamoto Y; Jinnin M; Kimura H; Kobayashi T; Iwama S; Arima H; Matsuoka T
Endocrinol Metab (Seoul); 2022 Feb; 37(1):84-95. PubMed ID: 35255603
[TBL] [Abstract][Full Text] [Related]
2. Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.
Cho YK; Jung CH
Diabetes Metab J; 2023 Nov; 47(6):757-766. PubMed ID: 37482654
[TBL] [Abstract][Full Text] [Related]
3. Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?
Kyriacou A; Melson E; Chen W; Kempegowda P
Clin Med (Lond); 2020 Jul; 20(4):417-423. PubMed ID: 32675150
[TBL] [Abstract][Full Text] [Related]
4. Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus.
Wei HH; Lai YC; Lin G; Lin CW; Chang YC; Chang JW; Liou MJ; Chen IW
Diabetol Metab Syndr; 2024 Jan; 16(1):26. PubMed ID: 38254155
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy and delivery in an advanced cancer survivor with immune checkpoint inhibitor-induced type 1 diabetes: a case report.
Sugai K; Miwa T; Kojima J; Ueda Y; Tsukahara K; Nishi H; Suzuki R
Endocrine; 2024 Mar; ():. PubMed ID: 38502365
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option.
Greene A; Penner S; Kunesh J; Altaf A; McGrade W; Niu J
J Oncol Pharm Pract; 2024 Mar; ():10781552241241493. PubMed ID: 38544442
[TBL] [Abstract][Full Text] [Related]
7. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors.
Ponvilawan B; Khan AW; Subramanian J; Bansal D
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539558
[TBL] [Abstract][Full Text] [Related]
8. Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria.
Angelousi A; Ziogas DC; Siampanopoulou V; Mytareli C; Anastasopoulou A; Lyrarakis G; Gogas H
Diseases; 2024 Feb; 12(2):. PubMed ID: 38391787
[TBL] [Abstract][Full Text] [Related]
9. Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.
Motomura Y; Urai S; Hirota Y; Takegawa N; Bando H; Yamamoto M; Fukuoka H; Tsuda M; Ogawa W
Diabetol Int; 2024 Jan; 15(1):130-134. PubMed ID: 38264226
[TBL] [Abstract][Full Text] [Related]
10. Key Determinants of Immune-Mediated Adverse Reactions to Oncology Drugs.
Zhou Y; Ding S
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067327
[TBL] [Abstract][Full Text] [Related]
11. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and human leukocyte antigens in patients with immune checkpoint inhibitor-induced type 1 diabetes and pituitary dysfunction: a single center prospective study.
Hara N; Suwanai H; Yakou F; Ishii K; Iwasaki H; Abe H; Shikuma J; Sakai H; Miwa T; Suzuki R
Endocrine; 2023 Sep; 81(3):477-483. PubMed ID: 37178310
[TBL] [Abstract][Full Text] [Related]
13. Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors.
Inaba H; Morita S; Kosugi D; Asai Y; Kaido Y; Ito S; Hirobata T; Inoue G; Yamamoto Y; Jinnin M; Kimura H; Ota M; Okudaira Y; Nakatani H; Kobayashi T; Iwama S; Arima H; Matsuoka T
Front Immunol; 2023; 14():1165004. PubMed ID: 37114039
[TBL] [Abstract][Full Text] [Related]
14. Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events.
Les I; Martínez M; Pérez-Francisco I; Cabero M; Teijeira L; Arrazubi V; Torrego N; Campillo-Calatayud A; Elejalde I; Kochan G; Escors D
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900420
[TBL] [Abstract][Full Text] [Related]
15. Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment.
Shalit A; Sarantis P; Koustas E; Trifylli EM; Matthaios D; Karamouzis MV
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672324
[TBL] [Abstract][Full Text] [Related]
16. Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice.
Rodríguez de Vera-Gómez P; Piñar-Gutiérrez A; Guerrero-Vázquez R; Bellido V; Morales-Portillo C; Sancho-Márquez MP; Espejo-García P; Gros-Herguido N; López-Gallardo G; Martínez-Brocca MA; Soto-Moreno A
J Diabetes Res; 2022; 2022():4508633. PubMed ID: 36387939
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.
Issa M; Tang J; Guo Y; Coss C; Mace TA; Bischof J; Phelps M; Presley CJ; Owen DH
Expert Rev Anticancer Ther; 2022 Aug; 22(8):861-874. PubMed ID: 35786142
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
